Search

Clinical trials

The advance of highly innovative, increasingly personalized therapies in hematology requires novel clinical trial designs and more flexible, adaptive regulatory frameworks and improved data generation to support decision making both during and after clinical studies.

Read more

Quality of Life and Symptoms

The goals of the SWG are:

To promote the evaluation of patient-reported outcomes (PROs) in hematology in daily clinical practice and in clinical trials.

Read more

Chronic Myeloid Leukemia

The objective of this SWG is the cure of Chronic Myeloid Leukemia (CML) by cooperative research.

Read more

EHA Awards 2011 at the 16th Congress of EHA in London

Bob Löwenberg will be the fourth recipient of the Jean Bernard Lifetime Achievement Award which was presented for the first time at the 13th Annual Congress in Copenhagen.

Read more

Diagnosis in hematological diseases: morphology and flow cytometry

This SWG is active in disseminating knowledge on advances in the diagnosis and follow-up by morphology and multiparameter flow-cytometry of malignant and non-malignant hematological diseases. These include morphology, digital morphology, and flow-cytometry (mass, imaging, and spectral flow cytometry included).

Read more

Immune Therapies for Hematologic Disorders

Recently the treatment of hematological and solid malignancies has been revolutionized by the introduction of novel immunotherapeutic strategies.

Read more

Highlights from the SWG

SWG AML Annual Scientific MeetingThe most recent SWG AML Annual Scientific Meeting took place during the annual EHA Congress in Frankfurt, Germany.

Read more

Myelodysplastic Syndromes (MDS)

The SWG on Myelodysplastic Syndromes (MDS) focuses on the promotion and exchange of scientific and clinical evidence, ideas and projects in the field of MDS.

Read more